Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Sell
43
ZVSA Quote, Financials, Valuation and Earnings
Last price:
$0.95
Seasonality move
:
-46.45%
Day range:
$0.86 - $1.11
52-week range:
$0.55 - $8.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.31x
Volume:
2.2M
Avg. volume:
4.2M
1-year change:
-85.23%
Market cap:
$2.7M
Revenue:
--
EPS (TTM):
-$113.75
Analysts' Opinion
-
Consensus RatingZyVersa Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $70.00, ZyVersa Therapeutics has an estimated upside of 1786.79% from its current price of $1.06.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $1.06.
Fair Value
-
According to the consensus of 1 analyst, ZyVersa Therapeutics has 1786.79% upside to fair value with a price target of $70.00 per share.
ZVSA vs. S&P 500
-
Over the past 5 trading days, ZyVersa Therapeutics has overperformed the S&P 500 by 67.83% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ZyVersa Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ZyVersa Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter ZyVersa Therapeutics reported revenues of --.
Earnings Growth
-
ZyVersa Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ZyVersa Therapeutics reported earnings per share of -$2.43.
Enterprise value:
1.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$13M | -$14.4M | -$9.1M | -$1.8M | -$1.3M | |
| EBITDA | -$13.6M | -$14.4M | -$9.1M | -$1.8M | -$1.3M | |
| Diluted EPS | -$782.07 | -$3,116.02 | -$81.40 | -$32.92 | -$0.57 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $811.8K | $6.4M | $3.4M | $1.7M | |
| Total Assets | -- | $1.1M | $118.5M | $22.1M | $20.6M | |
| Current Liabilities | -- | $13.6M | $8.2M | $10.2M | $11.2M | |
| Total Liabilities | -- | $13.6M | $18.5M | $11M | $12.1M | |
| Total Equity | -- | -$12.5M | $100M | $11.1M | $8.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.5M | -$8.7M | -$7.6M | -$2.8M | -$1.2M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $1.9M | $6M | $6M | $4.3M | $2.6M | |
| Free Cash Flow | -$1.5M | -$8.7M | -$7.6M | -$2.8M | -$1.2M | |
ZVSA
Sector
Market Cap
$2.7M
$33.7M
Price % of 52-Week High
13.17%
40%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-85.23%
-46.85%
Beta (5-Year)
--
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.74
200-day SMA
Sell
Level
$2.02
Bollinger Bands (100)
Sell
Level
0.86 - 1.34
Chaikin Money Flow
Sell
Level
-202.6M
20-day SMA
Buy
Level
$0.74
Relative Strength Index (RSI14)
Buy
Level
59.37
ADX Line
Buy
Level
35.54
Williams %R
Neutral
Level
-63.3823
50-day SMA
Buy
Level
$1.01
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
396.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Stock Forecast FAQ
In the current month, ZVSA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ZVSA average analyst price target in the past 3 months is $70.00.
-
Where Will ZyVersa Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that ZyVersa Therapeutics share price will rise to $70.00 per share over the next 12 months.
-
What Do Analysts Say About ZyVersa Therapeutics?
Analysts are divided on their view about ZyVersa Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ZyVersa Therapeutics is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is ZyVersa Therapeutics's Price Target?
The price target for ZyVersa Therapeutics over the next 1-year time period is forecast to be $70.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ZVSA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ZyVersa Therapeutics is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ZVSA?
You can purchase shares of ZyVersa Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ZyVersa Therapeutics shares.
-
What Is The ZyVersa Therapeutics Share Price Today?
ZyVersa Therapeutics was last trading at $0.95 per share. This represents the most recent stock quote for ZyVersa Therapeutics. Yesterday, ZyVersa Therapeutics closed at $1.06 per share.
-
How To Buy ZyVersa Therapeutics Stock Online?
In order to purchase ZyVersa Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
33
BULZ alert for Apr 10
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 15.46% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 12.84% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 13.04% over the past day.
